ICH News
- Welcome to the Institute's new Internet
- Stem cell technique offers new potential to treat blindness
- 20% of adult obesity might be caused by infant nutrition
- Study to reduce birth defects
- Beta thalassaemia gene therapy success
- Genetic link with human male infertility identified
- New research into Congenital Toxoplasmosis endorses UK health guidance for pregnant women
- ICH Poster Competition and Open Day
- Is 'breast only' for first six months best?
- Six months of exclusive breast feeding: how good is the evidence?
- Major new programme to tackle childhood obesity launched
- Study shows that early detection of Severe Combined Immunodeficiency would save lives
- £28 Million boost to understand child health
- The impact of sex selection and abortion in China, India and South Korea
- Regenerative medicine success for muscles
- New study examines early-onset eating disorders in under-13s
- International 50-year mortality trends in children and young people reveal an inadequate response to the health problems and causes of death in adolescents, particularly young men
- Apples, oranges and jam – the tasty way to keep kidney disease at bay
- Scientists prove heart has built-in repair mechanism: Exciting breakthrough towards mending broken hearts
- Fight for Sight awards £1 million for retinal disease research
- New Policy Research Unit in the Health of Children, Young People and Families
- UCLB and NCYPE announce a commercialisation agreement with Special Products Limited for Epistatus®
- Molecular scalpel hope for Duchenne muscular dystrophy
- Eating disorders linked to fertility problems and negative feelings towards pregnancy
- Science: From Cradle to Grave
- £36 million boost for children's health research
- Gene therapy success for children born without functioning immune system
- ICH Open Day 2011
- Under 16s make up less than one per cent of NHS patient surveys
- Mitochondria genes and cardiomyopathy
- Child Health Research PhD Studentships 2012-13
- Tate Liverpool exhibition inspires pioneering science games
- No consistent decrease in child maltreatment despite years of policy initiatives designed to achieve it
- New approach on bone marrow transplant infections
- Genetic testing for antibiotic related deafness
- Great Ormond Street Hospital Children’s Charity announces plans to build a Centre for Children’s Rare Disease Research
- Gene therapy shows clinical effect in third immune disease
- Clean delivery kits linked to substantial reduction in neonatal deaths in South Asia, study shows
- Genetic variant inherited from the mother significantly increases birth weight
- Not enough is known about prescription drug use in pregnancy, say experts
- Improving access to education and employment and reducing the risk of transport-related injury are among the best ways to improve adolescent health
- Research reveals association between red hair gene and rare birthmarks
- Five new UCL fellows of Academy of Medical Sciences
- Surgery boost for children with drug-resistant epilepsy.
- Professor of economics and deputy director appointed to the new UK Birth Cohort Study
- First example of a heritable abnormality affecting semantic cognition found
- New Director of the UCL Institute of Child Health
- New approach to recording suspected child abuse in patient records
- Amniotic fluid yields alternatives to embryonic stem cells
- ICH OPEN DAY AND POSTER COMPETITION
- Europe’s first research centre to battle birth defects
- New cause of thyroid hormone deficiency discovered
- £10 million boost for Centre for Children’s Rare Disease Research
- EU awards grant to develop new drug for Duchenne muscular dystrophy
- New research centre for teenagers with arthritis
- Major study shows steep decline in figure for diagnosed epilepsy
- Obesity leads to vitamin D deficiency
Quick Links
UCLB and NCYPE announce a commercialisation agreement with Special Products Limited for Epistatus®
25 July 2011
UCL Business PLC (UCLB) and the National Centre for Young People with Epilepsy (NCYPE), a specialist epilepsy charity, have signed a commercialisation agreement with Special Products Limited, a specialty pharmaceutical company focused on niche therapeutic areas, in preparation for the marketing of the Special Product’s proprietary epilepsy treatment Epistatus® as a licensed medicine.
Professor Brian Neville and Dr Rod Scott from UCL’s Institute of Child Health (ICH) and NCYPE have been closely involved in the development of Epistatus® since the inception of the product 10 years ago.
Special Products is currently seeking UK marketing authorisation for Epistatus®, which has been distributed internationally as an unlicensed medicine for more than 10 years on compassionate use. Epistatus®, a proprietary buccal formulation of midazolam maleate, is used to stop an epileptic seizure from developing into status epilepticus, a life-threatening condition.
Special Products filed for marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) earlier this year. Once the product is approved in the UK, it is intended that the marketing authorisation will be extended to other European countries and selected world markets.
The negotiation of this agreement was supported by Dr Chris Williams, UCLB Business Manager (BioPharm), who is responsible for ICH’s intellectual property. Chris commented: ‘We are pleased to have completed this agreement with Special Products, and look forward to seeing Epistatus® become widely available for patients as a licensed medicine.’
Page last modified on 25 jul 11 10:15
